A Phase 1 stem cell clinical trial for Multiple Sclerosis (MS) will be conducted by the researchers at Tisch Multiple Sclerosis Research Center New York. MS is a chronic human autoimmune disease that leads to myelin damage and neurodegeneration and impacts approximately 2.1 million people worldwide.
The groundbreaking study will investigate a regenerative strategy using stem cells harvested from the patient’s own bone marrow. These stem cells will be injected intrathecally (into cerebrospinal fluid surrounding the spinal cord) in 20 participants who meet the inclusion criteria for the trial. This will be an opensafety and tolerability study. All study activities will be conducted at the Tisch MS Research Center and affiliated International Multiple Sclerosis Management Practice (IMSMP).
The clinical application of autologous neural progenitors in MS is the culmination of a decade of stem cell research conducted by a dedicated team of scientists headed by Dr. Sadiq and by Dr. Violane Harris, Research Scientist at Tisch MS Research Center.
Preclinical testing found that the injection of these cells may decrease brain inflammation and promote myelin repair and/or neuroprotection. “This study exemplifies the Tisch MS Research Center’s dedication to translational research and provides a hope that established disability may be reversed in MS,” Dr. Sadiq noted.
Participants will undergo a single bone marrow collection procedure, from which mesenchymal stem cell-derived neural progenitor cells (MSC-NPs) will be isolated, expanded and tested prior to injection. Participants will receive three rounds of injections at three month intervals. Safety and efficacy parameters will be evaluated in all participants through regular follow-up visits.
About Tisch MS Research Center of New York — For over twenty years, Dr. Saud A. Sadiq has believed that combining excellence in clinical care with innovative research targeted at finding the cure for multiple sclerosis would set an exemplary standard in the treatment of MS patients. Today, the Tisch MS Research Center of New York embodies this new model of healthcare, in which your doctor is also your researcher. Dr. Sadiq helps those with MS by conducting cutting-edge, patient -based research to ensure unparalleled care. The close relationship of the non-profit research center and its affiliated clinical practice (IMSMP) enables the testing to new MS treatments and accelerates the pace at which research discoveries move from lab bench to bedside. The Tish MS Research Center of New York aims to identify the disease trigger, optimize treatments for patients, and repair the damage caused by multiple sclerosis.
Read more – www.digitaljournal.com